ライフサイエンスコーパス: alpha-myosin

1 re not significantly different compared with alpha-myosin.

2 ed by chimeric myosin was similar to that of alpha-myosin, almost twice the velocities observed with

3 deficient mice was consistent with decreased alpha myosin and increased beta myosin heavy chains, sug

4 alpha-Myosin and beta-myosin isoform mRNAs were affected

5 tion increased the actin-sliding velocity of alpha-myosin by 20% and beta-myosin by 36% compared with

6 tion increased the actin sliding velocity of alpha-myosin by 20% and beta-myosin by 36%, compared to

7 us (AdMYH6) to deliver the full-length human alpha-myosin gene to adult rabbit and human cardiac myoc

8 r peroxisome proliferator-activated receptor-alpha (myosin heavy chain [MHC]-PPARalpha mice) exhibit

9 of atrial myosin light chain 2 (MLC-2a) and alpha myosin heavy chain (alpha-MHC).

10 s accompanied by repression of genes such as alpha myosin heavy chain (alphaMyHC) and SERCA2A and the

11 In mice, CD4+ T cells specific for cardiac alpha myosin heavy chain (alphaMYHC) cause myocarditis a

12 r the control of the cardiac muscle-specific alpha myosin heavy chain (MHC) gene promoter.

13 evealed significantly elevated expression of alpha myosin heavy chain (MHC) isoform in epicardial fib

14 rated increased heart-to-body weight ratios, alpha myosin heavy chain and cardiac isoprostane levels,

15 Our results demonstrate that the beta-alpha myosin heavy chain intergenic DNA possesses a bidi

16 on of Gata4 by Cre recombinase driven by the alpha myosin heavy chain promoter did not selectively af

17 Using the alpha myosin heavy chain promoter to target expression o

18 s CAG promoter or the cardiomyocyte-specific alpha myosin heavy chain promoter, we identify a rare po

19 targeted manner in the heart using a murine alpha myosin heavy chain promoter.

20 by an Arg403-->Gln missense mutation in the alpha-myosin heavy chain (403) is affected by chronicall

21 ional assays, PURalpha and PURbeta repressed alpha-myosin heavy chain (alpha-MHC) gene expression in

22 AMP-inducible expression of the rat cardiac alpha-myosin heavy chain (alpha-MHC) gene in cardiac myo

23 ible E-box/M-CAT hybrid motif in the cardiac alpha-myosin heavy chain (alpha-MHC) gene promoter.

24 R)-beta (Delta337T-TR-beta(1)) driven by the alpha-myosin heavy chain (alpha-MHC) gene promoter.

25 onstruct was under the control of the murine alpha-myosin heavy chain (alpha-MHC) promoter, and ion c

26 FATP)1 in the heart under the control of the alpha-myosin heavy chain (alpha-MHC) promoter.

27 sing PPARgamma1 in the heart via the cardiac alpha-myosin heavy chain (alpha-MHC) promoter.

28 ult cardiomyocytes in mice primarily express alpha-myosin heavy chain (alpha-MHC, also known as Myh6)

29 The alpha-myosin heavy chain (alpha-MyHC) is the major contr

30 inned cardiac myocytes that contained either alpha-myosin heavy chain (alpha-MyHC) or beta-MyHC at 12

31 he mouse heart, which contains predominantly alpha-myosin heavy chain (alpha-MyHC), the applicability

32 (beta-MyHC) and reduced expression of adult alpha-myosin heavy chain (alpha-MyHC), with the net outc

33 (sACT) was increased, whereas expression for alpha-myosin heavy chain (alphaMHC) and the sarcoplasmic

34 ility, which results from down-regulation of alpha-myosin heavy chain (alphaMHC) and up-regulation of

35 Initial results using the mouse alpha-myosin heavy chain (alphaMHC) promoter resulted in

36 In this study, we used the alpha-myosin heavy chain (alphaMHC) promoter to generate

37 CrePR1 driven by the alpha-myosin heavy chain (alphaMHC) promoter was express

38 ompared the gene expression profiles between alpha-myosin heavy chain (alphaMHC)-BMP10 transgenic hea

39 alpha-Myosin heavy chain (alphaMHC)-mTORkd mice had a ne

40 use hearts bearing the R403Q mutation in the alpha-myosin heavy chain (alphaMHC403/+).

41 show that YY1 is a negative regulator of the alpha-myosin heavy chain (alphaMyHC) gene, which, with b

42 In vitro, Cre driven by cardiac-specific alpha-myosin heavy chain (alphaMyHC) sequences elicited

43 mice regulated by cardiac lineage promoters alpha-myosin heavy chain (alphaMyHC), Nkx2.5, or Mef2C.

44 is a single-copy transgene controlled by an alpha-myosin heavy chain (aMHC) promoter and coding for

45 d two disease-inducing peptides from cardiac alpha-myosin heavy chain (CAMHC).

46 of the HCM-causing Arg403Gln mutation in the alpha-myosin heavy chain (MHC) gene is inhibited by doxy

47 The expression of the alpha-myosin heavy chain (MHC) gene is restricted primar

48 the heart using the cardiomyocyte- specific alpha-myosin heavy chain (MHC) promoter led to approxima

49 tation is a missense substitution, I820N, in alpha-myosin heavy chain (MYH6), a structural protein ex

50 mutations in the actin-binding domain of the alpha-myosin heavy chain (MyHC) gene displays many pheno

51 T3 and NE also increased alpha-myosin heavy chain (MyHC) mRNA and reduced beta-My

52 generated cardiac-specific MDA5 transgenic (alpha-myosin heavy chain [alphaMHC]-MDA5) mice.

53 As in the left ventricle, decrease in alpha-myosin heavy chain and a switch towards glycolysis

54 he SRF target genes skeletal alpha-actin and alpha-myosin heavy chain and blocked differentiation of

55 the mRNAs encoding the contractile proteins, alpha-myosin heavy chain and cardiac alpha-actin, and th

56 fetal genes, reversing, in part, changes in alpha-myosin heavy chain and sarcoplasmic reticulum Ca2+

57 y method was used to study mice harboring an alpha-myosin heavy chain Arg403Gln missense mutation (al

58 c ablation of SRF by crossing the transgenic alpha-myosin heavy chain Cre recombinase line with SRF L

59 ghtly later deletion of calcineurin with the alpha-myosin heavy chain Cre transgene resulted in letha

60 intracellular reactive oxygen species (ROS), alpha-myosin heavy chain expression (alpha-MHC), and int

61 from embryoid bodies was inhibited, whereas alpha-myosin heavy chain expression and myosin-stained c

62 baseline, accompanied by upregulation of the alpha-myosin heavy chain gene and increases in cardiac f

63 On a soy diet, males with a mutation in the alpha-myosin heavy chain gene progress to dilation and h

64 ene consisting of the cardiomyocyte-specific alpha-myosin heavy chain gene promoter and the A3AR cDNA

65 modulin cDNA was placed under control of the alpha-myosin heavy chain gene promoter to overexpress tr

66 tal muscle TnT transgene driven by a cardiac alpha-myosin heavy chain gene promoter.

67 1B-adrenergic receptor (AR) using the murine alpha-myosin heavy chain gene promoter.

68 y acid transport protein 1 (FATP1) using the alpha-myosin heavy chain gene promoter.

69 the b-type natriuretic peptide gene, and the alpha-myosin heavy chain gene.

70 2.9 kb of 5' flanking sequence from the rat alpha-myosin heavy chain gene.

71 The alpha-myosin heavy chain is a principal molecule of the

72 We show alpha-myosin heavy chain MerCreMer and the MLC-2v promot

73 myocardium expressed substantial amounts of alpha-myosin heavy chain mRNA (alpha-MHC, 23-34% of tota

74 rcoplasmic-reticulum calcium ATPase mRNA and alpha-myosin heavy chain mRNA and a decrease in beta-myo

75 rozygotes and demonstrated downregulation of alpha-myosin heavy chain only in Gata4/Tbx5 heterozygote

76 induced in BALB/c mice by immunization with alpha-myosin heavy chain peptide and complete Freund's a

77 p406-425 peptide derived from mouse cardiac alpha-myosin heavy chain preferentially develop a predom

78 CIP1) under control of the cardiac-specific, alpha-myosin heavy chain promoter (alpha-MHC).

79 we generated transgenic mice containing the alpha-myosin heavy chain promoter (alphaMHC) placed prox

80 fic expression of PPARgamma is driven by the alpha-myosin heavy chain promoter (alphaMHC-PPARgamma) w

81 the tetracycline-regulated, cardiac-specific alpha-myosin heavy chain promoter (V1A-TG).

82 mice were created using the cardiac-specific alpha-myosin heavy chain promoter and rat A1AR cDNA.

83 essing tamoxifen-inducible Cre driven by the alpha-myosin heavy chain promoter are increasingly used

84 ional regulatory elements located within the alpha-myosin heavy chain promoter can be manipulated to

85 ice expressing ATF3 under the control of the alpha-myosin heavy chain promoter have atrial enlargemen

86 rexpressing human Bcl-2 under the control of alpha-myosin heavy chain promoter into allogenic C57BL/6

87 the Tmod1-null mice under the control of the alpha-myosin heavy chain promoter Tg(alphaMHC-Tmod1).

88 Using the alpha-myosin heavy chain promoter to direct cardiac spec

89 With the use of the alpha-myosin heavy chain promoter to direct cardiac-spec

90 We used the heart-selective alpha-myosin heavy chain promoter to drive expression in

91 We used the alpha-myosin heavy chain promoter to drive expression of

92 nder control of the tetracycline-repressible alpha-myosin heavy chain promoter underwent echocardiogr

93 endogenous ACE gene under the control of the alpha-myosin heavy chain promoter using targeted homolog

94 This down-regulation of the alpha-myosin heavy chain promoter was accomplished by th

95 skeletal actin promoter 1.7-fold whereas the alpha-myosin heavy chain promoter was unaffected.

96 The cardiac-restricted alpha-myosin heavy chain promoter was used to target exp

97 the HIF-1alpha gene under the control of the alpha-myosin heavy chain promoter were constructed.

98 oA under the control of the cardiac-specific alpha-myosin heavy chain promoter were generated.

99 e overexpression of iNOS in transgenic mice (alpha-myosin heavy chain promoter) did not induce contra

100 by E11, mediated by Cre under control of the alpha-myosin heavy chain promoter), animals survived to

101 inhibitor for Rho family proteins, using the alpha-myosin heavy chain promoter, active at embryonic d

102 r gene under control of the cardiac-specific alpha-myosin heavy chain promoter, resulting in rhythmic

103 ion beta-tropomyosin mice by turning off the alpha-myosin heavy chain promoter, which is driving the

104 AK) on cardiogenesis in mouse ES cells using alpha-myosin heavy chain promoter-driven enhanced green

105 A, each driven by the cardiomyocyte-specific alpha-myosin heavy chain promoter.

106 verexpressing Bcl-2 under the control of the alpha-myosin heavy chain promoter.

107 ATP sensitivity under control of the cardiac alpha-myosin heavy chain promoter.

108 domains (MerCreMer) under the control of the alpha-myosin heavy chain promoter.

109 utant of the PKCepsilon isoform driven by an alpha-myosin heavy chain promoter.

110 lear dominant negative CELF protein under an alpha-myosin heavy chain promoter.

111 r in the hearts of transgenic mice using the alpha-myosin heavy chain promoter.

112 pression of MLC2v was achieved by use of the alpha-myosin heavy chain promoter.

113 A1a in the heart, using the cardiac-specific alpha-myosin heavy chain promoter.

114 IGF-1B was placed under the control of a rat alpha-myosin heavy chain promoter.

115 se specifically in the mouse heart using the alpha-myosin heavy chain promoter.

116 pha coding sequence was driven by the murine alpha-myosin heavy chain promoter.

117 smooth muscle gamma-actin using the cardiac alpha-myosin heavy chain promoter.

118 Expression was driven by the murine alpha-myosin heavy chain promoter.

119 sed wild-type Galphaq in the heart using the alpha-myosin heavy chain promoter.

120 in the heart, driven by the cardiac-specific alpha-myosin heavy chain promoter.

121 GF-1B) was placed under the control of a rat alpha-myosin heavy chain promoter.

122 atal cardiomyocytes under the control of the alpha-myosin heavy chain promoter.

123 R and constitutively active (ca) mTOR, using alpha-myosin heavy chain promoter.

124 rexpression of CYP2J2 was achieved using the alpha-myosin heavy chain promoter.

125 ardiomyocytes were generated using the mouse alpha-myosin heavy chain promoter.

126 entricular myocytes under the control of the alpha-myosin heavy chain promoter.

127 in which expression was driven by the mouse alpha-myosin heavy chain promoter.

128 ively active mutant of Akt linked to the rat alpha-myosin heavy chain promoter.

129 These mice were crossed with alpha-myosin heavy chain reverse transcriptional transac

130 Downregulation of alpha-myosin heavy chain was restored by the treatment,

131 plasmic reticulum Ca2+-ATPase (SERCA)-2a and alpha-myosin heavy chain were reduced in hypothyroidism,

132 promoters (Skeletal alpha-actin, Desmin, and alpha-Myosin heavy chain) in skeletal and cardiac myocyt

133 utant mouse model of FHC (Arg403Gln knockin, alpha-myosin heavy chain).

134 se3 was induced by using the rat promoter of alpha-myosin heavy chain, a model that may represent a u

135 cteristic of cardiomyocytes, such as cardiac alpha-myosin heavy chain, cardiac troponin I and T, atri

136 ch as those encoding cardiac alpha-actin and alpha-myosin heavy chain, in an SRF-dependent manner in

137 diac-specific transcripts, including cardiac alpha-myosin heavy chain, troponin C, myosin light chain

138 lt mouse hearts, which predominantly express alpha-myosin heavy chain, we observed high concentration

139 ic promoters, including the alpha-actins and alpha-myosin heavy chain, were selectively and potently

140 n of CLP-1 haplodeficiency in the transgenic alpha-myosin heavy chain-angiotensinogen mice causes pro

141 crossbred into a mouse genetic model of CHF (alpha-myosin heavy chain-calsequestrin), MCK-EcSOD trans

142 cyte-specific LKB1 knock-out (KO) mice using alpha-myosin heavy chain-Cre deletor strain.

143 reviously, we described transgenic mice with alpha-myosin heavy chain-directed expression of a consti

144 art failure based on cardiac phenotypes from alpha-myosin heavy chain-directed overexpression mice.

145 ted cardiac-specific ILK knockout mice using alpha-myosin heavy chain-driven Cre expression.

146 new line of evidence for the differentiated alpha-myosin heavy chain-expressing cardiomyocyte as the

147 ven by the promoter for the cardiac-specific alpha-myosin heavy chain.

148 in and indirect targets such as myogenin and alpha-myosin heavy chain.

149 KAG2 gene with the cardiac-specific promoter alpha-myosin heavy chain.

150 DR4-HRE but also in some genes, such as rat alpha-myosin heavy-chain and S14 genes, containing the D

151 -sarcoglycan mutation in the heart using the alpha-myosin heavy-chain gene promoter.

152 The cre recombinase transgene driven by the alpha-myosin heavy-chain promoter deleted the floxed ET(

153 pase has physiological actions, we placed an alpha-myosin heavy-chain promoter upstream of a human li

154 using conditional ROCK2(flox/flox) mice and alpha-myosin heavy-chain promoter-driven Cre recombinase

155 eceptor gamma 1 (PPARgamma1) via the cardiac alpha-myosin heavy-chain promoter.

156 ed and crossed into merCremer mice under the alpha-myosin heavy-chain promoter.

157 inhibitor for Rho family proteins, using the alpha-myosin heavy-chain promoter.

158 of this study was to determine whether fast alpha-myosin molecular motor gene transfer can confer ca

159 Fast alpha-myosin motor expression was determined by Western

160 inotropy in failing cardiac myocytes by fast alpha-myosin motor protein gene transfer.

161 osin isoform mRNAs were affected by CAN, but alpha-myosin mRNA was reduced more in nontransgenic mice

162 ic abnormalities in FHC mice with a specific alpha-myosin mutation, and also validate a novel method

163 autoimmune myocarditis by immunization with alpha-myosin-peptide; 20 mice served as controls.

164 to insufficient thymic negative selection of alpha-myosin-reactive T cells.

165 quences of either Loop 1+Loop 2 or Loop 2 of alpha-myosin were exchanged for those of beta-myosin wer